Impact of Minimally Invasive Surgery on Early and Late Outcomes of Patients With Gastric Cancer Treated Using Neoadjuvant Chemotherapy
MIS after neoadjuvant chemotherapy for gastric cancer appears to be a viable option, with oncological outcomes comparable to those of OG, less blood loss, and shorter hospital stays. Although MIS did not independently affect long-term survival, it offered potential benefits in terms of postoperative recovery and morbidity. Further studies are needed to validate these findings, especially across diverse populations.
Authors
- Sílvio Melo Torres (ORCID: https://orcid.org/0000-0001-7274-3602)
- André L. Godoy (ORCID: https://orcid.org/0000-0002-7154-1184)
- Alessandro Landskron Diniz (ORCID: https://orcid.org/0000-0001-9671-2026)
- Gustavo Ferreira Araruna (ORCID: https://orcid.org/0000-0003-4502-8624)
- Igor Correia de Farias
- Héber Salvador de Castro Ribeiro (ORCID: https://orcid.org/0000-0002-3412-7451)
- Wilson Luiz da Costa (ORCID: https://orcid.org/0000-0003-4460-4706)
- Felipe José Fernández Coimbra (ORCID: https://orcid.org/0000-0001-5068-0639)
Institutions
- Baylor College of Medicine (US)
- AC Camargo Hospital (BR)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/jso.27904
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.26